Abstract
Each year, infectious diseases are responsible for millions of deaths, most of which occur in the rural areas of developing countries. Many of the infectious disease diagnostic tools used today require a great deal of time, a laboratory setting, and trained personnel. Due to this, the need for effective point-of-care (POC) diagnostic tools is greatly increasing with an emphasis on affordability, portability, sensitivity, specificity, timeliness, and ease of use. In this review article, we discuss the various diagnostic modalities that have been utilized towards this end and are being further developed to create POC diagnostic technologies, and we focus on potential effectiveness in resource-limited settings. The main modalities discussed herein are optical-, electrochemical-, magnetic-, and colorimetric-based modalities utilized in diagnostic technologies for infectious diseases. Each of these modalities feature pros and cons when considering application in POC settings, but overall reveal a promising outlook for the future of this field of technological development.
Keywords: point-of-care, infectious diseases, diagnosis, detection, biosensors
Graphical Abstract
In the fight against infectious diseases, reaching an accurate and timely diagnosis is often important in order to make an informed decision about the treatment plan. A rapid and accurate diagnosis allows clinicians to prescribe the proper medical treatment and greatly improves patient prognosis overall. When dealing with infectious diseases in particular, a timely diagnosis is even more crucial and may reduce or prevent further infection within the patient population. World Health Organization (WHO) has emphasized the importance of creating POC tests and created a set of criteria for evaluating POC tests. These criteria are summarized by the acronym ASSURED (Affordable, Sensitive, Specific, User-Friendly, Robust and rapid, Equipment free, Deliverable), which represents the characteristics needed for an ideal POC platform.1–3 Despite the attention given to the development of novel diagnostic and treatment methods, infectious diseases continue to pose a major threat to the global population.4–7 Respiratory infections such as pneumonia, influenza, and tuberculosis remain some of the most prolific causes of infectious disease deaths, resulting in nearly 5 million reported deaths each year. This is roughly twice as many as the reported HIV/AIDS-related deaths (2.5 million deaths annually). Malaria and diarrheal diseases account for an additional 1.2 and 2.2 million deaths, respectively, each year.8–10 Overall, infectious diseases caused by bacteria, viruses, parasites and fungi result in 15 million deaths each year, and approximately 95% of these deaths occur in low- to middle-income countries.8,11
While there are many effective methods for the detection of pathogenic agents, such as culturing, microscopy, genomic amplification (e.g., PCR) and immunoassays (e.g., ELISA), these approaches each have their own shortcomings and are less applicable in resource-limited settings where infectious diseases are more prevalent. Culturing is a very lengthy process, often requiring multiple days or weeks to produce results, in which time the infection can advance within the patient and be transmitted throughout the population. Furthermore, the empirical use of antibiotics is commonly pursued while bacterial culture results are pending, which risks increasing the prevalence of antibiotic resistant bacteria. While more efficient with regards to time, microscopy is limited in both scope and application in POC settings, as it is restricted to pathogens able to be visualized at low magnification.4,8,12
Further diagnostic methods such as polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) are more efficient with regard to time and scope but have several drawbacks. Immunoassays can be successfully utilized to detect infectious diseases if the correct antibody-antigen interaction is determined but are difficult to develop and use for the detection of pathogens with high rates of epitope mutation. Additionally, PCR and ELISA often require the use of expensive laboratory equipment and trained professionals.13–15 Unfortunately, there are many regions of the world in which this environment is simply not available or sustainable. Due to this, it is common for biological samples to be collected and transported to the nearest laboratory facility or hospital capable of performing such complex laboratory procedures, often a great distance away. Once delivered, lab results are obtained, and the results are sent back, often days or weeks later. After receiving the results, the physician must then contact the patient in order begin proper treatment. The inefficiency of this protocol calls for the development of alternative POC diagnostic methods that may be used in smaller, regional medical clinics that do not have the capabilities for traditional diagnostic techniques. To be effective, these methods must be timely, cost-effective, relatively simple, and reasonably portable.16
Recently, a number of diagnostic platforms have been developed to detect pathogenic biomarkers (DNA/RNA, glycoproteins, enzymes, antibodies, etc.) with the aforementioned qualities, such as speed, simplicity and cost-effectiveness.1,17 These biosensors are often based on nano- or micro-technology platforms and they commonly rely on the production of optical, electrical, magnetic or visually detectable signals. Positive detection signals are produced when the sensors encounter pathogens or pathogen byproducts. While the mechanisms used to produce positive signals vary, the goal remains the same across the board: sensitive and timely detection of infectious pathogens. Many of these platforms are undergoing further optimization for use in POC settings, with the goal of being able to detect the desired biomarker within one hour. In many countries patients do not live with nearby access to health care, and it is often not feasible for them to come in on two separate days, one to provide a biological sample and second time to collect results and begin treatment. Additionally, many live far enough away that they may rarely travel to locations with health care access, therefore diagnostic techniques must be created that can be brought to the patient. While there are several POC diagnostic tools widely used today in the community and clinics with minimal laboratory capabilities, only a small handful of infectious diseases can be detected currently. These include malaria with Binax NOW, tuberculosis (TB) with Xpert MTB/RIF, and HIV with several different lateral flow assays among others. Furthermore, the use of smartphone-based diagnostics is increasing such as MobiNAAT recently designed to detect Chlamydia trachomatis.2,18–23
There are many difficulties in developing POC diagnostics that are realistically applicable. In order to increase the number of effective POC diagnostic tools, additional biosensors must be developed with certain capabilities in mind. Firstly, the must be able to detect biomarkers in trace quantities and in complex media such as blood, sputum, or environmental samples, such as food and/or water. Further difficulties arise when considering the complex pathogenesis undergone by many infectious agents, such as bacteria, viruses, or parasites. Certain pathogens may remain in the blood or sputum longer than others and may only produce certain biomarkers at specific stages in their life cycle. For this reason, optimal biosensors are those that can be customized for more than just one biomarker, allowing them to detect multiple pathogens throughout various stages in their life cycle. Furthermore, POC diagnostic techniques aim to be easily utilized with minimal training in a setting that cannot support a full laboratory.
Despite these significant hurdles, much progress has been made in this field. However, realistic implementation is not always the focus of many developing diagnostics, and it is the goal of this paper to outline various novel POC platforms that may soon move from the lab into clinical settings. The biosensors discussed herein are divided into categories based upon the modality used for detection. The ASSURED criteria are often not reported for diagnostic platforms in early development, so those discussed herein are evaluated based on critical POC characteristics such as level of detection (LOD), timelines, cost, detection capabilities in complex media, and other factors relating to the effectiveness of the platforms in resource-limited-settings.
Detection Modalities
There are many different approaches to developing diagnostic platforms, but in this paper the focus will be on the development of optical-, electrochemical-, magnetic-, and colorimetric-based modalities. Furthermore, there are many different techniques that fall under the modalities listed, but a few of the most commonly studied techniques are highlighted within each section with everything else grouped under the category of other. An outline of the various infectious diseases that have been successfully detected in a number of studies can be found in Tables 1–4, with a few described in further detail in the rest of this work.
Table 1:
Information about optical-based POC tests being developed including technique, target pathogen, LOD, timeliness, and any additional features mentioned in the study.
Technique | Target Pathogen | LOD | Speed | Additional features | Citation |
---|---|---|---|---|---|
Quantum dot fluorescence polarization analysis using bifunctional aptamer binding | Influenza (H1N1 DNA) | Detection limit: 3.45 nM | NR | Detects DNA sample so prep is needed. Not real sample. | Zhang et al.33 |
Strand displacement amplification with fluorescence polarization | M. tuberculosis | 1 genome | 3 h | Detected DNA isolated from culture, sample prep required. | Walker et al.34 |
Strand displacement amplification with fluorescence polarization | M. tuberculosis | 10 genomes | 20 min | Detected DNA isolated from culture, sample prep required. | Walker et al.36 |
Fluorescent nanoparticle-based indirect immunofluorescence microscopy | M. tuberculosis | 3.6E5 cells/mL | 4 h | In mixed bacteria and spiked sputum samples | Qin et al.35 |
Fluorescence polarization-based nucleic acid detection | Salmonella spp. | 1 CFU | 20 min | Can differentiate between S. Typhi and S. Paratyphi in blood samples. Cost: $1. | Park et al.30 |
Fluorescence polarization immunoassay | Brucella spp | NR | 5 min | Specificity 97.9% and sensitivity 96.1%. Detects in serum. | Lucero et al.37 |
Localized SPR-based AuNP-alloyed quantum dot nanobiosensor | Influenza (H3N2) | H3N2: 10 PFU/mL | 5 min | Differentiated between H3N2 and H7N7/H9N2. Detection in water and human serum. | Takemura et al.41 |
Influenza (H1N1) | H1N1: 0.03 pg/mL in water and 0.4 pg/mL in human serum | ||||
Quantum dot barcode technology with smartphones and isothermal amplification | HIV or hepatitis B | 1000 viral genetic copies per milliliter | 1 h | Can detect multiple pathogens at once. Detects amplified DNA so sample prep needed. | Ming et al.42 |
Nanobioprobes utilizing fluorescent quantum dots | Avian influenza virus (H9N2) | 8.94 ng/mL | NR | Utilizes S. Aureus to make the nanobioprobes. | Xiong et al.43 |
Integrated portable microsystem with PCR amplification and capillary electrophoretic analysis coupled with electrical control and laser-excited fluorescence detection | E. coli and S. Aureus | 2–3 bacterial cells | 10 min | Detected cells suspended in water | Lagelly et al.47 |
Microfluidic chip with integrated PCR and electrophoretic analysis | BK virus | 1–2 viral copies | NR | Identifies viral loads. Detected PCR product from urine samples. | Kalgala et al.49 |
Bead-based immunofluorescence-assay on a microfluidic dielectrophoresis platform | Dengue | 1E4 PFU/mL | 5 min | Chip is reusable >50×. | Iswardy et al.60 |
Microfluidic chip capable of performing DNA/RNA amplification, electrokinetic sample injection and separation, and on-line optical detection of nucleic acid products | S. pneumoniae and Dengue-2 virus | NR | <5 min | - | Huang et al.51 |
Microfluidic device integrated with microvalves and micropumps for rapid DNA hybridization using shuttle flow | 4 serotypes of Dengue | 100 pM | 90 s | Sample consumption of 1 microliter. Could differentiate between the 4 sero types of dengue. Detect each simultaneously. | Huang et al.52 |
Magnetic immunofluorescence assay using portable device equipped with optical fiber spectrometer and a microfluidic device | Avian influenza (H9N2) | 3.7E4 copy/μL | 55 min | Sample consumption of 2 microliters. Complex biological samples including fresh dung, liver, and lung. Differentiated H9N2 vs H5N1/H1N1. | Zhang et al.46 |
On-chip pressure injection utilizing DNA amplification via non-contact infrared-mediated polymerase PCR and microchip electrophoresis. | S. typhimurium | <1000 starting copies of DNA | 12 min | Detected amplified DNA | Easley et al.53 |
Microfluidic integration of nanoplasmonic biosensor composed of a microarray of gold nanohole sensors | C. trachomatis and N. gonorrhoeae | Chlamydia trachomatis: 300 CFU/mL Neisseria gonorrhoeae: 1500 CFU/ml |
< 1 h | Simultaneous detection in urine samples | Soler et al.54 |
Plastic-chip-based magnetophoretic immunoassay using magnetic and gold nanoparticles modified with M. tuberculosis antibodies | M. tuberculosis | 1.8 pg/ml | 1 h | Detection in sputum. Can differentiate between other mycobacterium. Cost <$2 per assay | Kim et al.57 |
Glass chip optical analytical system developed by integrating microarray and fabricating gold nanoparticles | Avian Influenza (H5N1 and H9N2) | 1 pg/mL | NR | - | Park et al.61 |
Dual-molecular affinity-based Förster (fluorescence) resonance energy transfer platform using fluorescent vancomycin−gold nanoclusters and aptamer−gold nanoparticles | S. aureus | 10 CFU/mL | 30 min | The limit of detections in the diluted milk, orange juice, and human serum sample for S. aureus are 300, 100, and 100 cfu/mL | Yu et al.59 |
Table 4:
Information about colorimetric-based POC tests being developed including technique, target pathogen, LOD, timeliness, and any additional features mentioned in the studies.
Technique | Target Pathogen | LOD | Speed | Additional features | Citation |
---|---|---|---|---|---|
Lateral flow test using nitrocellulose membrane and adsorbed onto colloidal gold particles to | M. tuberculosis | NR | 15 min | Sensitivity and specificity >90% | Gonzalez et al.122 |
Lateral flow assay which pairs a nucleic acid aptamer with an antibody | Influenza | 2E6 viral particles | 15 min | Can differentiate between subtypes | Le et al.123 |
Smartphone-based fluorescent diagnostic device | Influenza | H7N1: 5.34E2 PFU/mL H9N2: 1.37E1 PFU/mL |
15 min | H5N1 Sensitivity: 96.55% Specificity: 98.55% |
Yeo et al.124 |
Lateral flow biosensor using loop-mediated isothermal amplification and gold nanoparticles | E. faecalis | 710 CFU/mL | 75 min | Detection in spiked blood samples | Wang et al.125 |
S. aureus | 680 CFU/mL | ||||
Displacement amplification label-based gold nanoparticles lateral flow biosensor | L. monocytogenes | 10 fg of genomic templates per reaction in pure culture | 1 h | Detection in pork samples. One time equipment cost: $600 USD Per assay: $6 |
Wang et al.126 |
Later flow assay using label-based gold nanoparticles with a multiple cross displacement amplification technique | Shigella | 10 fg of genomic templates per reaction in pure culture and 5.86 CFU per tube in human fecal samples | 1 h | Detection in human fecal samples | Wang et al.127 |
Multiplex LAMP label-based lateral flow dipstick biosensor using gold nanoparticles | Leptospira | 3.95 × 1E-1 genomic equivalent per reaction [Fig. | 1 h | - | Nurul Najian et al.129 |
Lateral flow assay using multicolored silver nanoparticles | Dengue, yellow fever, and ebola virus | 150ng/mL | NR | Can differentiate between dengue, yellow fever, and ebola viruses. | Yen et al.128 |
Naked-eye detection of nucleic acids using isothermal amplification and magnetic particle mediated aggregation | human papillomavirus | 5.1 amol | 60–120 min | Detection in blood sample | Lin et al.130 |
Label-free dual fluorescence for the visual product detection isothermal multiple-self-matching-initiated amplified DNA | hepatitis B virus | 10 copies of DNA | NR | - | Ding et al.131 |
Visual gene-detecting technique using nanoparticle gene probes and silver staining enhancement | Hepatitis B and C viruses | Hepatis B: 3.6E-11 M Hepatitis C: 3.6E-10 M |
3 h | - | Wang et al.132 |
Colorimetric assay that utilizes the chemical oxidation of 3,3′,5,5′-tetramethylbenzidine by isothermally functionalized DNA targets | M. tuberculosis | 1 CFU | 75 min | Cost: $3 per assay | Ng et al.133 |
Probe–based colorimetric assay using gold nanoparticles | M. tuberculosis | 0.75 μg of DNA | 2 h | Cost: $0.35 per sample Detection in sputum, bronchial washes, pleural effusion, urine, and blood |
Baptista et al.134 |
Dipstick visual detection using gold nanoparticles and aptamers | Influenza | 3E8 viral particles | NR | - | Le et al.135 |
Multiplexed kit capable with target-specific fluorescently tagged strand displaceable probes with RT-LAMP | Zika | ~0.71 pfu equivalent viral RNAs | 30 min | Detection in urine and plasma | Yaren et al.136 |
Dengue | ~1.22 pfu equivalent viral RNAs, | ||||
Chikungunya | ~38 copies of viral RNA | ||||
Immunochromatography dipstick test using monoclonal antibodies | Dengue and zika | NR | 1 h | Distinguishes between the four dengue serotypes and zika. Detection in serum. Dengue sensitivity/specificity: ranges from 76% to 100%. Zika sensitivity/specificity: 81/86% |
Bosch et al.139 |
Optical Detection
Optical-based detection of infectious diseases has been utilized in several attempts to design ideal POC platforms. While this modality has shown great potential, there are several pros and cons to be considered. Optical-based diagnostics rely on the sensitive detection of photon emission from dyes and molecules that are excitable by light. Often, fluorescent probes are designed which will only emit photons after interacting with targeted biomarkers, such as antibodies, antigens, or genomic material.24–26 Compared to other visualization techniques such as microscopy or enzyme-based detection, fluorescence emission allows increased sensitivity, adding to the reliability of this modality. Additionally, there are a wide variety of molecules that have intrinsic fluorescence qualities, which is one of the benefits of this technique that allows some degree of platform customization. However, intrinsic fluorescence properties of non-target molecules may also cause background noise and false positives, therefore this method usually requires somewhat clear sample solutions to prevent interference from other molecules.24,25 While there are many pros to using optical-based platforms, they often require technology not commonly found in resource limited settings such as filter fluorometers or spectrofluorometers, which increase the platform cost and complexity, and often limit its application in resource-poor settings.25,27 However many POC modalities being developed are overcoming this issue by combining optical-based technologies with smartphones to create more portable technologies.28 Finally, if this approach is used in immunoassays, many florescence molecules utilized as probes may interfere with the binding of antibodies to the antigen, which could prevent this platform from being used with the detection of certain diseases.25 Additionally, it is critical to control where the fluorescence molecule binds to prevent the antigen binding site from being occupied by the fluorescence molecule, this can be difficult in many cases.27
Optical Detection Utilizing Fluorescence Polarization
A commonly used fluorescence assay, fluorescence polarization (FP), involves the fluorescent tagging of a probe which is then allowed to interact with target molecules, resulting polarized light emission.25,27,29–31 FP is preferable to many other fluorescence based immunoassays because little sample preparation is need.27,32 This assay was utilized in several studies to detect influenza,33 Mycobacterium tuberculosis,34–36 Salmonella spp.,30 and Brucellosis spp.37 Walker et al. was able to detect M. tuberculosis in about 3 hours at levels as low as 1 TB genome. Later, they were able to make this test more rapid but slightly less sensitive and were able to detect 10 TB genomes in 20 minutes.34,36 FP was utilized by Ki Soo Park et al.30 for specific detection of Salmonella spp., as well as differentiation between different sub-types of Salmonella such as S. typhimurium and S. paratyphimurium. In blood samples, the bacterial detection reached a sensitivity of about 1 CFU/mL in less than 3 hours. They utilized a PCR based approach with DNA polymerase, complementary DNA to the target STY3007 and STY1121 genes in Salmonella spp., and a reporter probe conjugated with a single fluorophore. When mixed with a sample of Salmonella spp., the complementary DNA bound to the target genes and the free reporter probe emitted a high signal in an FP assay. On the other hand, when the target Salmonella spp. genes were not present in the sample, the DNA polymerase catalyzed the cleavage of the fluorophore from the reporter probe, resulting in low values in the FP assay. They calculated the cost of this test to be about $1 per test. This rapid and low-cost design shows great potential for use as a POC platform. However, because this assay requires the detection of intracellular components, additional sample preparation steps are required, such as DNA extraction in this case.
Optical Detection Utilizing Quantum Dots
Quantum Dots (QDs) are very small nanoparticles that act as semi-conductors that have strong fluorescence properties. QDs have been utilized to develop infectious disease diagnostic platforms in several studies.38–40
Kenshin Takemura et al.41 demonstrated a detection limit of 0.4pg/mL for H1N1 influenza utilizing CdSeTeS QDs. In another study done by Kevin Ming et al.42 a quantum dot-based detection platform was combined to develop a portable smartphone diagnostic tool for HIV and hepatitis B with a detection limit of 1000 viral genetic copies/mL and in less than 1 hour.
Another interesting application of fluorescence-based detection is demonstrated by Xiong et al. Functionalized Staphylococcus aureus cells with fluorescence were turned into nanobioprobes capable of targeting and detecting pathogens.43 Targeting is made possible through interactions between protein A which is expressed on the surface of S. aureus, and Fc region of selected monoclonal antibodies (mAbs). Since this assay targets surface proteins, minimal sample preparation is need. These mAbs may be used to target any selected virus or bacteria, however this study was conducted by specifically detecting H9N2 avian influenza virus. The conjugation of antibodies to the surface of these cellular nanoprobes does not require conjugation chemistry, as the Fc region of the antibodies and protein A have a strong binding affinity. Addition of the fluorescent modality is accomplished by synthesizing CdS0.5Se0.5 within the cell. When mixed with targeted viral glycoproteins, these nanobioprobes and immunomagnetic beads formed a sort of “sandwich” around the viral glycoprotein. The magnetic beads allow for the capture of the pathogen while the nanoprobes allow for its detection and subsequent quantification. As the concentration of the targeted viral glycoprotein decreased, the fluorescent signal responded accordingly, and the detection limit determined using this method was 8.94 ng/mL of targeted viral glycoprotein. The true strength of this technique is its ability to be easily targeted against multiple pathogens, due to the simplicity with which mAbs may be targeted to the S. aureus surface with no need for conjugation chemistry. These nanobioprobes also provide an approach to biosensor development using a functionalized organism, reducing environmental risks of toxicity often encountered when using inorganic nanomaterials. However, because these nanobioprobes are created with live bacteria it may be important to handle them with caution. Also, due to the potential mutations and variation in bacteria the consistency of these products may be reduced.
Optical Detection Utilizing Microfluidic Platforms
Several other studies have utilized optical based detection methods along with a microfluidic platform. Microfluidic technology has allowed for the creation of disposable, miniaturized devices that combine various steps into a compact space. Microfluidic devices can be customized to do DNA amplification, sample preparation, and detection all in one chip.17,40,44–46 Researchers have demonstrated the detection of Escherichia coli,47,48 S. aureus,47 BK virus,49 Dengue,50–52 avian influenza virus,46 Streptococcus pneumoniae,51 and S. typhimurium.53 Furthermore, one study utilized optical properties along with microfluidic technology to detect Chlamydia trachomatis and Neisseria gonorrhoeae at levels as low as 300 CFU/mL and 1500 CFU/mL respectively.54 Edwar Iswardy et al.50 utilized a dielectrophoresis chip with anti-flavivirus antibody coated bead to detect dengue virus. They reached detection times of about 5 minutes and the chip was reusable for more than 50 times. This rapid and low-cost platform demonstrates potentials of this microfluidic chip as a POC diagnostic tool.
Optical Detection with Other Nanotechnologies
Some studies are combining nanotechnology with fluorescent molecules to create diagnostic plat forms as was done in the study done by Banerjee et al.55 to detect E. coli. Other studies utilize the inherent optical properties, surface plasmon resonance (SPR), of gold nanoparticles (AuNPs).39,56 Diagnositic techniques utilizing AuNPs have been studied for the detection of M. tuberculosis,57 Influenza,58 and S. aureus.59 In the study done by Yu, Mengqun et al.59 a fluorescence resonance energy transfer platform was utilized to detect S. aureus detecting as low as 10 CFU/mL in under 30 minutes.
Electrochemical Detection
Electrochemical detection is currently being studied for potential POC diagnosis of infectious diseases. This is one of the most common modalities being researched and developed due to the potential for miniaturization, portability, and cost reductions.26,27 The glucometer is the most common example that utilizes this modality.62,63 Electrochemical detection modalities utilize biosensors that are capable of binding to a target molecule associated with the disease. When these probes bind to the target molecule, they undergo a conformational change and create a small current that can be detected. Unlike fluorescence-based detection, this modality is more easily utilized with non-clear samples such as blood.24 Additionally, electrochemical-based detection doesn’t require complex optical instrumentation that is used in many fluorescence-based detections. Electrochemical-based detection often uses instrumentation such as carbon electrodes and field effect transistor (FET) biosensor along with electrochemical analysis methods such as with differential pulse voltammetry (DPV) platforms. Some instrumentation has been made very portable, such as the hand held potentiostat. While these methods can be initially costly and complicated to utilize, the technology can evolve into more miniaturized and easy to use platforms as the development progresses.24,44,57,64–67
Electrochemical Detection Utilizing Field Effect Transistors
Additionally, various strains of avian influenza were detected using FET sensors with great success.66,68 The FET method has shown promise due to its portability, sensitivity, and ease of use.69 Hideshima et al.66 developed a FET biosensor capable of detection viral proteins within the attomolar concentration. Ultimately, the developed FET biosensor was able to detect and differentiate between H1 and H5 in attomolar concentrations, which means that this device is capable of detecting a single viral particle, since each viral particle displays roughly 500 hemagglutinin particles on its surface. Bovine Herpes Virus-1 was detected using FET biosensors in under 10 minutes, this method could be utilized with other infectious diseases.70 Furthermore, Savannah Afsahi et al.71 utilized similar FET methods to detect zika with concentrations as low as 450 pM in about 5 minutes.
Electrochemical Detection Utilizing Microfluidic Platforms
Microfluidic chips that utilize electrochemistry have become a popular choice for the development of POC diagnostic tools due to their sensitivity, portability, speed, and ease of use.63,72,73 Several studies have utilized a microfluidic platform along with electrochemistry to detect Streptococcus mutans and Pseudomonas aeruginosa,74 several strains of avian influenza,44,75,76 Salmonella spp.,44 cholera toxin,77 M. tuberculosis, Haemophilus influenza, and K. pneumonia.78 In the study done by Hsieh et al.44 researchers utilized a DNA probe with a redox reporter bound to a microfluidic chip. When complementary target DNA binds to the DNA probe, it undergoes a conformational change causing a change in the redox rate of the reporter which creates a current that can be detected. This biosensor cannot detect DNA levels naturally found in the blood, so PCR or loop mediated isothermal amplification (LAMP) is necessary to amplify the DNA. This study integrated LAMP into microfluidic chip to create a microfluidic electrochemical quantitative LAMP (MEQ-LAMP) device shown in Figure 1, in order to decrease cost and detection time in addition to decreasing the instrumentation needed for the detection. The MEQ-LAMP chip successfully detected Salmonella spp. at levels as low as 16 copies of DNA in under 50 minutes. Combining the preparation, amplification, and detection in one multiplex platform is a step towards an ideal POC platform.
Figure 1:
A) representation of MEQ-LAMP chip used by Hsieh et al. for the detection of Salmonella44 for infectious disease detection. B) The Methylene Blue molecule in this electrochemical setup allow for real-time detection of the LAMP reaction. Reprinted with permission from reference (79) Hsieh, K.; Patterson, A. S.; Ferguson, B. S.; Plaxco, K. W.; Soh, H. T. Rapid, sensitive, and quantitative detection of pathogenic DNA at the point of care through microfluidic electrochemical quantitative loop-mediated isothermal amplification. Angew. Chemie - Int. Ed. 2012, 51 (20), 4896–4900. Copyright 2012, John Wiley and Sons.
Electrochemical Detection Utilizing Nanotechnology
Several studies utilized nanotechnology along with electrochemistry to increase sensitivity levels in the detection of several infectious diseases.80,81 These methods have been utilized to detect influenza,65 M. tuberculosis,64,82 Clostridium difficile.83 One study utilized electrical signals to detect influenza virus particles using silver nanoparticles and was designed by Sepunaru et al.65 Silver nanoparticles are first adsorbed onto the virus surface when present together in solution. Upon the addition of a carbon electrode to the solution, current spikes are observed which correlate with the oxidation of the adsorbed nanoparticles. This method produces current spikes which are proportional in magnitude to the concentration of the virus in solution and may therefore be used to quantify viral levels as well as detect the pathogen. While this method is not able to determine the specific viral species, it is able to differentiate between viral and bacterial infections in a simple, POC applicable manner.
Another example of the utilization of electrochemical-based detection of M. tuberculosis with AuNPs is demonstrated by Benjamin Ng et al.64 This assay took advantage of the high binding affinity between streptavidin (SA) and biotin. M. tuberculosis DNA was extracted from M. tuberculosis cells and then isothermally amplified with biotin dUTPs to create a biotinylates product and then placed on a SA-coated disposable screen-printed carbon electrode (SPCE). AuNPs are conjugated with streptavidin and washed with BSA/PEG buffer; the BSA binds to any areas left exposed on the AuNPs to prevent unwanted interactions. Finally, these conjugated AuNPs are added to the SPCE, and the more AuNPs are bound to the SPCE, the higher the DPV signal indicating a positive result. Concentrations as low as 1 CFU of M. tuberculosis DNA were detected. Additionally, this assay was tested with a handheld potentiostat which can be used at POC sights because it can be powered by a laptop. The total cost per assay was about $10, and it could be completed in under 90 minutes.
Other Electrochemical Detection Methods
Impedance based electrochemical biosensors were used to detect Flaviviruses such as dengue and zika,84 influenza,85 HIV,86 and E. coli.87 Various electrochemical methods were also utilized to detect several bacterial strains such as M. Tuberculosis,88,89 E. coli,90 and Vibrio cholera.90 Another study utilized various electrochemical methods to detect HIV using microelectrode arrays.91
While detecting infectious diseases has been on the front lines of many research studies, identifying infectious disease resistance is just as important. In one study thin film transistor sensors were developed by Chunxiao Hu et al.92 to detect antimicrobial resistance genes for E. coli and Klebsiella pneumoniae. This method detected 100 copies of the genomic DNA in under 3 minutes.
Magnetic Detection
Magnetic detection of infectious disease agents utilizing magnetic nanoparticles (MNPs) is a growing field. This approach usually utilizes binding affinities between conjugated antibodies on MNPs and the target pathogen. There are two popular uses of MNPs for the detection of infectious diseases. The first utilizes the magnetic relaxation properties of the MNPs when they interact with water. MNPs conjugated with antibodies are placed in solution with the target pathogen and bind to one another, causing aggregates. This aggregation alters the spin-spin-spin relaxation time (T2) of the surrounding water protons which can be quantified by a magnetic resonance spectroscopy machine.4,96–100 The second utilizes magnetoresistive sensors (Figure 2). In this method, the antibody is fixed to a surface and the sample with the pathogen antigen is washed over it, resulting in binding. Then, MNPs conjugated with the antibody are washed over the same surface and bind to the antigen as well. This second binding of the MNPs alters the magnetic field and gives off an electrical signal that can be detected.38,96,101,102 Many of these assays are very rapid and take less than an hour for detection. Magnetic-facilitated detection is especially appealing for POC settings due to the nanoparticle’s ability to be manipulated in a magnetic field, which can decrease sample preparation time by utilizing magnetic field separation. Additionally, magnetic nanoparticle detection can provide signals in opaque samples such as blood, making this modality superior to light- and visual-based modalities in these cases. Furthermore, biological samples usually do not have ferromagnetism properties. This leads to very minimal background noise, which is commonly found with florescence detection methods.103 One draw-back to most magnetic nanoparticles such as iron oxide MNPs is that they do not possess intrinsic photophysical properties that many other nanoparticles possess, such as gold.38,104 While the assays are relatively inexpensive to run, the instrumentation needed is not very portable and can be expensive.38
Figure 2:
Sandwich type immunoassay based magnetoresistive sensors which can be utilized to detect various infectious diseases. (A) Antibody is fixed to a surface. (B) Analyte is washed over and allowed to bind to antibody. (C) Biotinylated antibody is washed over to create a sandwich of the analyte. (D) Magnetic nanotags bind to the biotinylated antibody to allow for quantitative detection. Reprinted with permission from reference (101) Osterfeld, S. J.; Yu, H.; Gaster, R. S.; Caramuta, S.; Xu, L.; Han, S.-J.; Hall, D. A.; Wilson, R. J.; Sun, S.; White, R. L.; Davis, R. W.; Pourmand, N.; Wang, S. X. Multiplex protein assays based on real-time magnetic nanotag sensing. Proc. Natl. Acad. Sci. 2008, 105 (52), 20637–20640. Copyright 2008, National Academy of Sciences, U.S.A
While magnetic-based infectious disease detection methods are less commonly studied, there have been a few promising studies conducted that have successfully detected several common infectious diseases, and many of these studies can be adapted to detect many other types of infectious diseases as well.
Magnetic Nanoparticles
Magnetic nanoparticles have been utilized in several studies to create potential POC diagnostic platforms for the detections of E. coli,55,105 influenza,106 S. typhimurium, S. aureus,105 and anthrax.107
Using superparamagnetic iron oxide nanoparticles, Shelby et al.106 designed biosensors capable of detecting and differentiating between influenza glycoproteins. The nanoparticle platform used in this approach is based upon a magnetic iron core surrounded by a polyacrylic acid coating. This coating provides stability in addition to the ability to functionalize the nanoparticle via conjugation of targeting molecules, such as mAbs. These molecules allow the nanoparticle to interact in a specific fashion with the desired pathogenic targets, which can then be observed by the collection of sensitive T2 data. In one study, these magnetic relaxation nanosensors (MRnS) were used to detect influenza glycoproteins (H1 and H5) in the nanomolar concentration. In addition, MRnS were able to differentiate between these glycoprotein variants, and could therefore be used to distinguish between influenza subtypes. Furthermore, detection of viral contaminants was accomplished within 30 minutes, is simple and relatively portable, requiring only a bench-top magnetic relaxometer for sample analysis. The MRnS are also stable and cost-effective to produce, making this approach a worthy candidate for POC diagnostics.
In an additional study conducted by Banerjee et al.,55 this same iron oxide platform was further functionalized with a fluorescent modality, allowing for the detection of pathogenic E. coli using both magnetic and fluorescent analysis. In this approach, the polyacrylic acid coating was loaded with fluorescent dyes. Following the collection of magnetic relaxation data, bacterial pellets are isolated via centrifugation, resuspended, and analyzed via fluorescence as shown in Figure 3. These magneto-fluorescent nanosensors (MFnS) were able to detect as little as 1 CFU of the desired pathogen (E. coli O157:H7) and were able to distinguish between other E. coli species, as well as heat-inactivated E. coli O157:H7. To further test the realistic effectiveness of MFnS, they were tested in complex media such as milk and lake water, and produced similar results, detecting as little as 1 CFU of the desired pathogen within 30 minutes.
Figure 3:
Iron oxide nanoparticles functionalized into MFnS with conjugated antibody and DiI dye when incubated with bacteria allows for the quantitative detection of the bacteria through magnetic resonance and optical detection. Reprinted with permission from reference (55) Banerjee, T.; Sulthana, S.; Shelby, T.; Heckert, B.; Jewell, J.; Woody, K.; Karimnia, V.; McAfee, J.; Santra, S. Multiparametric Magneto-fluorescent Nanosensors for the Ultrasensitive Detection of Escherichia coli O157:H7. ACS Infect. Dis. 2016, 2 (10), 667–673. Copyright 2016, American Chemical Society.
Magnetoresistive Sensors
Chih-Cheng Huang et al.108 have been working on developing an immunoassay based POC diagnostic platform with a giant magneto resistive biosensor. This technique is also being utilized for the diagnosis of TB with a detection limit of 104 cells/mL of BCG bacteria.109 Krishna Venkatramana et al.103 designed a magnetoresistive platform capable of detecting Influenza A virus. A magnetoresistive biosensor chip was designed and functionalized to easily bind amino groups. Influenza A antibodies were fixed to the biosensor and a sample with influenza A virus was added and allowed to bind. Next, biotinylated antibody was added and allowed to bind to the antigen, and the MNPs were washed over the top and bound to the biotin. Therefore, the number of MNPs was proportional to the amount of influenza A present. A bench-top system was used to detect the changes in magnetic field through a current. This assay detected viral concentrations as low as 1.5 × 102 TCID50/mL, which is more sensitive than ELISA. Furthermore, the magnetoresistive chip contains 64 sensor arrays which would allow the potential to conjugate various antibodies and detect different subtypes of virus or even various pathogens in a single assay. While the assay requires time and is somewhat complicated to perform, Venkatramana foresees the possibility of the assay being further developed into a handheld device.
Other Magnetic-Based Detection Methods
Although not as common in infectious disease diagnosis, AC susceptometry has been utilized in some studies. AC susceptometry along with LAMP was utilized by Bo Tian et al.110 to detect synthetic zika oligonucleotides at levels of 1 aM in 20% serum in about 27 minutes.
Additionally, there have been several other optomagnetic studies that have been demonstrate as well. The detection of V. cholera was demonstrated by Rebecca S. Bejhed et al.111 detecting levels of 5 pM in under 20 minutes. Finally, in another study done by Bo Tian et al,112 Salmonella was detected using a blu-ray optomagnetic method at levels as low as 8E4 CFU/mL in under 3 hours.
Kim Jeonghyo et al.57 utilized both magnetic properties and photophysical properties of nanoparticles to detect TB. Magnetic microparticles (MMPs) bought from Invitrogen and synthesized AuNPs were conjugated with two different antibodies that recognize the CFP-10 antigen found in the early stages of TB. The conjugated MMPs and AuNPs aggregated with the CFP-10 antigen to create a type of sandwich, which could then be removed using a neodymium-iron-boron magnet. The absorbance of the remaining AuNPs was then inversely correlated with the concentration of CFP-10 antigen present. Levels as low as 1.8 pg/ml were detected using this method in under an hour. This level of sensitivity and speed, along with the assay’s ease of operation and low cost ($2 per assay), make this platform another potential candidate for ideal POC detection. Furthermore, the instrumentation used to run these assays costs roughly $300, which is relatively cost-effective when compared to other laboratory equipment start-up costs.
Finally, a magnetic-based diagnostic technique for S. aureus113 was created with detection levels as low as ten bacteria in a 10-μl sample in under 15 minutes. Other magnetic-based detection methods for infectious diseases such M. tuberculosis57,114 and dengue115 have also shown promising results with a level of detection of 1E3 cells/mL for M. tuberculosis and 100 pg/ml for dengue.
Colorimetric and Lateral Flow Tests
One of the main goals of POC diagnostic research is the development of assays that do not rely on microscopes, relaxometers, a consistent supply of electricity, or expensive and bulky machinery. Towards this end, a number of assays have been developed that ideally allow the collection of detection results using the naked eye or minimal detector technologies, and often rely on colorimetric modalities or sedimentation. Lateral flow assays (LFA) are one such example and have been utilized for pregnancy tests and HIV tests. For this test, a nitrocellulose, nylon, paper, or other composite membrane is usually used in an antigen capture assay. These membranes are capable of capillary action, and therefore are self-sufficient. Labeled antibodies are bound to the membrane and the antigen sample is allowed to diffuse along the membrane. When the antigens bind to the labeled antibodies this results in a color change in the colorimetric molecule being used. This change can be visualized with the naked eye or with minimal assistance. These types of diagnostic techniques are very attractive because they often utilize very little to no instrumentation, are cost-effective, rapid, and can be easily interpreted with minimal training. On the down side, this technique is solely quantitative and cannot indicate the severity of the infection.4,25,117,118
Lateral Flow Detection
While there is a current urine lateral flow test on the market used to detect active TB in HIV-positive adults, it lacks required levels of sensitivity to be fully effective in clinical scenarios.119–121 In a different study, Jesus M. Gonzales et al.122 developed a lateral flow test that may be more applicable to POC settings using immunodominant epitopes derived from highly immunogenic M. tuberculosis cell-wall proteins. In this technique, peptides were conjugated to BSA and were used along with colloidal gold particles on nitrocellulose membrane to detect antibodies of TB patients. The prototype utilized a combination of 3 different peptides and had a specificity greater than 90%. This assay was able to determine positive/negative status within roughly 15 minutes and had minimal reaction towards latent TB and BCG vaccinated patients.
Thao T. Le et al.123 continued to develop their avian influenza detection into a lateral flow test prototype. There were able to differentiate between various strains of H3N2 and detect levels as low as 2E6 virus particles utilizing the more specific aptamers rather than antibodies along with gold nanoparticles in their dual recognition element lateral flow assay (DRELFA) approach. They compared this approach to the antibody-based LFA to show the superiority of DRELFA to the more common LFA approach (Figure 4). The high portability and ease of use of a lateral flow test makes this a potential POC diagnostic test.
Figure 4:
(A) H3N2/Panama was detected using DRELFA but did not cross react with the subtypes H3N2/Udorn and H3N2/Aichi, unlike (B) the antibody-LFA which cross reacted with the other subtypes. Reprinted from reference (123) Le, T. T.; Chang, P.; Benton, D.; John, W.; Iqbal, M.; Edward, A.; Cass, G. Dual Recognition Element Lateral Flow Assay (DRELFA) - Towards Multiplex Strain Specific Influenza Virus Detection. Anal. Chem. 2017, 89 (12), 6781–6786, under open access liscense CC-BY.
Furthermore, a study conducted by Seon-Ju Yeo et al.124 demonstrated the use of a lateral flow assay in conjunction with a light weight fluorescence reader connected to a smart phone for the detection of H5N1 avian influenza. A nitrocellulose strip was prepared with anti-influenza antibodies fixed to the test line on the membrane, and anti-mouse IgG antibodies were fixed to the control line. A bioconjugate was also created which consisted of anti-influenza antibodies conjugated to coumarin-derived dendrimers, which acted as the fluorophore. The bioconjugate and the sample with H5N1 viral particles were allowed to diffuse down the strip and the H5N1 particles bound to the test line while the bioconjugate bound to the H5N1, creating a sandwich type interaction. This assay is demonstrated in Figure 5. The fluorescence intensity on the test and control lines was then quantified using the smart phone detector. This assay reached sensitivity levels of 97% and detected H5N1 in about 15 minutes. In addition to these rapid and sensitive characteristics, the high portability of this device makes it a potential POC tool for the diagnosis of H5N1.
Figure 5:
Visual representation of a lateral flow type assay utilized to detect H1N1. The specimen is allowed to flow down the strip and the bioconjugate binds to the viral particles while the viral particles bind to the test line, creating a sandwich type interaction. Reprinted from reference (124) Yeo, S.; Choi, K.; Cuc, B. T.; Hong, N. N.; Bao, D. T.; Minh, N. Smartphone-Based Fluorescent Diagnostic System for Highly Pathogenic H5N1 Viruses. Theranostics 2016, 6 (2), under open access liscence CC BY-NC.
Utilizing lateral flow assays several studies were able to detect several other infectious diseases such as Enterococcus faecalis, S. aureus,125 Listeria monocytogenes,126 Shigella,127 Dengue, Yellow Fever, Ebola,128 and Leptospirosis.129 The E. faecalis and S. aureus lateral flow tests were successfully developed by Li Wang et al.125 which could be utilized in about 75 minutes, detecting levels as low as 710 CFU/mL for E. faecalis and 680 CFU/mL for S. aureus.
Other Colorimetric Detection Methods
In addition to lateral-flow assays, aggregation and sedimentation-based diagnostic techniques also allow for naked-eye detection. These methods often involve the use of particles which change in color when aggregated, such as gold nanoparticles, or the use of natural coagulants which result in visual sedimentation. Some such studies have developed rapid visual detection of bacteria and viruses such as enterovirus 71,130 hepatitis B,131,132 hepatitis C,132 papillomavirus,130 M. tuberculosis,122,133,134 avian and human influenza,124,135 zika, chikungunya, and dengue.136 Another study utilized engineered phages for colorimetric detection of E. coli.137
One study visually detected M. tuberculosis in 2 hours with a cost of $0.35 per test.134 Furthermore, Jermey D. Driskell et al.138 utilized a similar technique using AuNPs with dynamic light scattering to detect the influence virus <100 TCID50/mL in under 30 minutes. Another detection method for influenza was developed by Le et al. who developed a platform utilizing gold nanoparticles that allowed for the visual detection of as little as 3E8 viral particles.135 The gold nanoparticles were assembled with RNA aptamers that allowed for specific affinity with different strains of human influenza. Aptamers were selected in place of targeting mAbs due to cost effectiveness, as they are 1/1,000th the price per molecule. In the presence of viral contaminants, the functionalized nanoparticles form a gold nanoshell (AuNS) around the virus. This increase in mass allows for the sedimentation of viral contaminants, which can be facilitated with a portable mini-centrifuge. After 6–10 min of centrifugation at 2000 × g, visual sedimentation of nanoparticle-coated virus was reported within the range of the typical viral load in 1mL of human respiratory specimens.
While there are tests being developed to detect flaviviruses136 there have been problems with differentiating between the various flaviviruses because of their structural similarities. Irene Bosch et al.139 however, recently developed a dipstick type detection method to not only detect, but also differentiate between zika and dengue in an assay that take about 20 minutes.
Another unique POC diagnostic tool being developed uses not visual detection methods, but olfactory. This study utilized AuNPs and fragrance substrate molecules to detect E. coli by emission of a smell. Levels as low as 1E2 CFU/mL were able to be detected in about 15 min.140
Discussion and Conclusion
As the need for rapid and accurate POC diagnostic tools continues to become more apparent, many platforms are being developed utilizing various methods and modalities. While many demonstrate impressive capabilities to detect pathogens or biomarkers in controlled lab environment, it is crucial to consider the characteristics required for realistic implementation throughout the entire development process. Each modality has its own pros and cons, but with careful planning, they all have the potential to facilitate successful POC diagnosis.
POC platforms utilizing optical modalities have a great deal of potential for customization due to the large numbers of fluorescent molecules available. This modality has been used in many of the platforms discussed throughout this review, however it also faces some limitations, such as the sample preparation required to eliminate background noise from the intrinsic florescence properties many molecules have. The goal of POC diagnostic tools is to use raw samples such as blood, serum or urine with minimal to no preparation, so florescence-based platforms are often not ideal in this aspect. Additionally, the benchtop technologies required are costly and require trained personal, further limiting its application in resource-limited settings where equipment is not easy to acquire. The ultimate goal of POC diagnostic technologies is to allow untrained personnel to easily utilize it in a portable manner.
Electrochemical POC diagnostic technology development has the most potential for miniaturization and portability, but its development alone can take a long time and be very costly. A large number of studies have developed potential prototypes that are portable and accurate, but these technologies still have a way to go before they are evaluated for effectiveness in the field. The glucometer is a good example of the potential for electrochemical diagnostic platforms, and it will not be surprising to see similar platforms reach the frontlines of POC detection in the near future.
The utilization of the magnetic properties of some nanoparticles allows for many of the downfalls of fluorescence detection methods to be overcome because this method can be utilized in opaque and non-processed solutions. Furthermore, the ability of magnetic nanoparticles to be manipulated by a magnetic field allows for a great deal of customization in development of various diagnostic tools. However, the current lack of portability and cost of the required machinery limit the utilization of many of these platforms as POC diagnostic tools. These hurdles will have to be overcome before they reach their full potential.
The colorimetric and lateral flow tests have had the most success in today’s POC market as can be seen with HIV POC diagnosis and pregnancy tests. Several studies are in the process of developing similar platforms for other infectious diseases, and aim to be equally as rapid, accurate, portable and simple to use. Although lateral flow assays are purely qualitative, they seem to be an attractive option for many developing POC tests due to ease of use and little equipment requirements.
Overall, each modality has the potential for becoming an effective POC diagnostic tool but require further optimization and clinical testing before they reach their full potential. A summary of the pros and cons of each platform discussed within this review can be found in Tables 1–4. Many POC tests that have recently been implemented in clinical settings are colorimetric-based diagnostic technologies such as dipsticks and lateral flow assays. Currently there are POC colorimetric platforms being utilized that allow for the detection of HIV, malaria, leptospirosis, typhoid fever, human African trypanosomiasis, and visceral leishmaniasis. Paper based assays such as many lateral flow assays seem to be an attractive platform because no lab, power source, or sophisticated equipment is required.2,19–22,141 In addition to the success of these simpler assays, the increasingly rapid advancement of technology promises to offer new solutions to old problems, seen already with the increasing number of phone-based platforms in development. While there are many innovative platforms of all kinds currently in development, it remains of utmost importance to consider the qualities needed for realistic implementation of these POC platforms at each stage in development. A focus on such qualities as timeliness, affordability, specificity, sensitivity, simplicity and portability will increase the rate at which these novel technologies leave the lab and find their place in the real world.
Table 2:
Information about electrochemical-based POC tests being developed including technique, target pathogen, LOD, timeliness, and any additional features mentioned in the study.
Technique | Target Pathogen | LOD | Speed | Additional Features | Citation |
---|---|---|---|---|---|
Nanowire field effect transistors using nanowire arrays modified with antibodies for influenza A | Influenza and adenovirus | 50 virons/microliter | NR | Can detection two viruses in parallel | Patolsky et al.68 |
Glycan-immobilized field effect transistor (FET) biosensor | Influenza | 60 H5 HA molecules and 6000 H1 HA molecules in 20 μL samples | NR | Can differentiate between H1 and H5 | Hideshima et al.66 |
Direct potentiometric serological diagnosis using extended-gate field-effect transistor containing MOSFET transducer and gold-coated chip | Bovine Herpes Virus-1 | 1:100 serum dilution | 10 min | Detection in serum. | Tarasov et al.70 |
Portable graphene-enabled biosensor using specific immobilized monoclonal antibody | Zika | 450 pM | 5 min | - | Afsahi et al.71 |
Multiplexed detection of bacterial cells with microfluidic chip using antimicrobial peptides | S. mutans and P. aeruginosa | 1E5 CFU/mL | 25 min | - | Lillehoj et al.74 |
Bead based microfluidic chip detection using voltammetry and paramagnetic beads made with CdS quantum dots | Influenza (H5N1) | NR | 45 min | - | Krejcova et al.75 |
Label-free detection using microfluidic chip integrated with an RGO-based electrochemical immunosensor | Influenza (H1N1) | 0.5 PFU/mL | 15 min | - | Singh et al.76 |
Micro-fluidic detector which employs a high-gradient magnetic field, on-chip RT-PCR, single-stranded DNA generation, and sequence-specific E-DNA detection. | Influenza (H1N1) | 10 TCID50 | 3.5 h | Detection from throat swabs | Hsieh et al.44 |
Electrochemical DNA sensor in a microfluidic chip format with loop-mediated isothermal amplification | S. enterica subsp. enterica serovars Typhimurium and Choleraesuis | 6.9 × 104 CFU/mL | 2 h | Detection in whole blood and could differentiate between S. typhimurium and S. cholerasuis | Hsieh et al.44 |
Microfluidic electrochemical platform with loop-mediated isothermal amplification | Salmonella genomic DNA | 16 copies | 50 min | Can determine viral load | Hsieh et al.44 |
Microfluidic immunosensor with Cholera toxin subunit B (CTB)-specific antibodies immobilized onto superparamagnetic beads | Cholera toxin | 9.0 ng/mL | 1.5 h | Detection in fecal samples | Bunyakul et al.77 |
Differentiation of bacteria using multiplex microfluidic chip with on chip loop-mediated isothermal amplification | M. tuberculosis | 28 copies/μL | 45 min | Detection in bacteria culture samples | Luo et al.93 |
H. influenza | 17 copies/μL | ||||
K. pneumonia | 16 copies/μL | ||||
Nano-electrochemical technique using silver nanoparticles | influenza | Single virus | NR | - | Sepunaru et al.65 |
Electrochemical bioassay using colloidal gold nanoparticles | M. Tuberculosis | 1 CFU | 90 min | Can be done using a portable potentiostat | Ng et al.94 |
Electrochemical aptasensor developed using coil-like fullerene-doped polyaniline, gold nanoparticles and aptamers | M. Tuberculosis (MPT64) | 20 fg/mL | NR | Detection in human serum | Bai et al.82 |
Electrochemical immunoassay using layer-by-layer coating carbon nanotubes and graphene oxide as a nanocarrier | C. difficile (toxin B) | 0.7 pg/mL | 45 min | Detection in human stool samples | Fang et al.83 |
Electrochemical capacitive sensing | Dengue, zika, and chikungunya (NS1) | 0.5 ng/mL | NR | Detection in serum | Cecchetto et al.84 |
Impedimetric glycan-based biosensor | Influenza H3N2 | 13 viral particles in 1 μl | NR | Differentiation shown between H3N2 and H7N7 | Hushegyi et al.85 |
Label free electrochemical immunosensor using an anti-ESAT-6monoclonal antibody | M. tuberculosis (ESAT-6) | 7 ng/mL | NR | Can discriminate between culture filtrate proteins from pathogenic mycobacteria strains and BCG non-virulent mycobacteria vaccine strain. | Diouani et al.95 |
Electrochemical DNA hybridization biosensor using a gold nanotubes array electrode platform | M. tuberculosis | 0.05 ng/μL | NR | - | Torati et al.89 |
Electrochemical detection using multifunctional nanoconjugates and subsequent signal amplification | E. coli O157:H7 | 39 CFU/mL | NR | Can detect 2 types of bacteria simultaneously | Li et al.90 |
V. cholera O1 | 32 CFU/mL | ||||
Label-free biosensor using faradaic electrochemical impedance spectroscopy | E. coli | 1E2 to 1E3 CFU/mL | 30 min | - | Guo et al.87 |
Electrochemical detection using allosteric enzymes and coulometry. | Anti-HIV antibodies | 4μM | 1 h | Detection in serum | Laczka et al.91 |
Label-free electrochemical sensor using streptavidin-coated magnetic beads | HIV-1 (subtypes A, B, C, D, E, and G) | 1.17 × 1E8 −8.39 × 1E8 copies/mL | 30 min | - | Shafiee et al.86 |
Thin-film transistor nanoribbon sensor | E. coli and K. pneumoniae | <10 copies of genomic DNA | 5 min | - | Hu et al.92 |
Table 3:
Information about magnetic-based POC tests being developed including technique, target pathogen, LOD, timeliness, and any additional features mentioned in the study.
Technique | Target Pathogen | LOD | Speed | Additional features | Citation |
---|---|---|---|---|---|
Magnetic relaxation nanosensor detection using ironoxide nanoparticles | Influenza (H5N1 and H1N1) | 1 nM | <30 min | Differentiation shown between H5N1 and H1N1 | Shelby et al.116 |
Magneto-fluorescent nanosensors detection ultilizing changes in T2 relaxation time | E. coli | 1 CFU | 30 min | - | Banerjee et al.55 |
Magnetoresistive biosensor | BCG bacteria | 1E4 cells/mL | NR | - | Barroso et al.109 |
Giant magnetoresistance biosensor using monoclonal antibodies and magnetic nanoparticles | Influenza | 1.5E2 TCID50/mL virus | 1 min | - | Krishna et al.103 |
Detection using loop-mediated isothermal amplification, AC susceptometry, and magnetic nanoparticles | Zika virus oligonucleotide | 1 aM | 27 min | Detection in 20% serum. Can use a portable AC susceptometer. | Tian et al.110 |
AC magnetic field detection method using oligonucleotide-tagged magnetic beads | V. cholera DNA | 10 pM | 60 min | - | Bejhed et al.111 |
Blu-ray optomagnetic detection | S. typhimurium and E. coli | 8E4 CFU/mL | 3 h | Can simultaneously detect S. typhimurium and E. coli | Tian et al.112 |
Detection using handheld diagnostic magnetic resonance system | S. aureus | 10 bacteria in a 10-μl sample | <15 min | - | Lee et al.113 |
Microchip-based sensor using magnetic bead bioassay platform | Dengue (anti-dengue virus IgG) | 100 pg/ml | NR | - | Aytur et al.115 |
Magnetic barcoding detection by nuclear magnetic resonance | M. tuberculosis | 1E3 cells/mL | 2.5 h | One-time equipment cost: $4,300 Per assay: $3 Detection in spiked sputum |
Liong et al.114 |
ACKNOWLEDGMENT
This project was supported by the National Institute of Health (NIH: 1 R03 AI132832–01) and Kansas INBRE grants (K-INBRE P20 GM103418), all to SS.
Abbreviations
- POC
point-of-care
- WHO
World Health Organization
- ASSURED
Affordable, Sensitive, Specific, User-Friendly, Robust and rapid, Equipment free, Deliverable
- PCR
polymerase chain reaction
- ELISA
enzyme-linked immunosorbent assay
- TB
tuberculosis
- LOD
level of detection
- FP
fluorescence polarization
- QDs
Quantum Dots
- mAbs
monoclonal antibodies
- SPR
surface plasmon resonance
- AuNPs
gold nanoparticles
- FET
field effect transistor
- DPV
differential pulse voltammetry
- LAMP
loop mediated isothermal amplification
- MEQ-LAMP
microfluidic electrochemical quantitative LAMP
- SA
streptavidin
- SPCE
screen-printed carbon electrode
- MNPs
magnetic nanoparticles
- T2
spin-spin relaxation time
- MRnS
magnetic relaxation nanosensors
- MFnS
magneto-fluorescent nanosensors
- MMPs
magnetic microparticles
- LFA
lateral flow assay
- DRELFA
dual recognition element lateral flow assay
Footnotes
The authors declare no conflict of interest.
REFERENCES
- (1).Peeling RW; Mabey D Point-of-care tests for diagnosing infections in the developing world. Clin. Microbiol. Infect 2010, 16 (8), 1062–1069 DOI: 10.1111/j.1469-0691.2010.03279.x. [DOI] [PubMed] [Google Scholar]
- (2).Pai NP; Vadnais C; Denkinger C; Engel N; Pai M Point-of-Care Testing for Infectious Diseases: Diversity, Complexity, and Barriers in Low- And Middle-Income Countries. PLoS Med 2012, 9 (9) DOI: 10.1371/journal.pmed.1001306. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (3).St John A; Price CP Existing and Emerging Technologies for Point-of-Care Testing. Clin. Biochem. Rev 2014, 35 (3), 155–167. [PMC free article] [PubMed] [Google Scholar]
- (4).Ly Sin M; Mach KE; Wong PK; Liao JC Advances and challenges in biosensor-based diagnosis of infectious diseases. Expert Rev. Mol. Diagn 2014, 1–20 DOI: 10.1586/14737159.2014.888313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (5).Franca RF; da Silva CC; De Paula SO Recent advances in molecular medicine techniques for the diagnosis, prevention, and control of infectious diseases. Eur J Clin Microbiol Infect Dis 2013. DOI: 10.1007/s10096-013-1813-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (6).Fauci AS; Morens DM The Perpetual Challenge of Infectious Diseases. N. Engl. J. Med 2012, 366 (5), 454–461 DOI: 10.1056/NEJMra1108296. [DOI] [PubMed] [Google Scholar]
- (7).Yager P; Domingo GJ; Gerdes J Point-of-Care Diagnostics for Global Health. Annu. Rev. Biomed. Eng 2008, 10 (1), 107–144 DOI: 10.1146/annurev.bioeng.10.061807.160524. [DOI] [PubMed] [Google Scholar]
- (8).Qasim M; Lim D-J; Park H; Na D Nanotechnology for Diagnosis and Treatment of Infectious Diseases. J. Nanosci. Nanotechnol 2014, 14 (10), 7374–7387 DOI: 10.1166/jnn.2014.9578. [DOI] [PubMed] [Google Scholar]
- (9).Morens DM; Folkers GK; Fauci AS The callenge of emerging and re-emerging infectious diseases. Nature 2004, 430, 243–249 DOI: 10.1038/nature02759. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (10).Morens DM; Folkers GK; Fauci AS The challenge of emerging and re-emerging infectious diseases. Nature 2010, 463 (7277), 122–122 DOI: 10.1038/nature08554. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (11).Millet JP; Moreno A; Fina L; Del Baño L; Orcau A; De Olalla PG; Caylà JA Factors that influence current tuberculosis epidemiology. European Spine Journal 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (12).Vidic J; Manzano M; Chang C-M; Jaffrezic-Renault N Advanced biosensors for detection of pathogens related to livestock and poultry. Vet. Res 2018, 48 (1), 11 DOI: 10.1186/s13567-017-0418-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (13).Sosnik A; Amiji M Nanotechnology solutions for infectious diseases in developing nations. Adv. Drug Deliv. Rev 2010, 62 (4–5), 375–377 DOI: 10.1016/j.addr.2009.11.010. [DOI] [PubMed] [Google Scholar]
- (14).Hartman LJ; Coyne SR; Norwood DA Development of a novel internal positive control for Taqman based assays. Mol Cell Probes 2005, 19 (1), 51–59 DOI: 10.1016/j.mcp.2004.07.006. [DOI] [PubMed] [Google Scholar]
- (15).Tighe PJ; Ryder RR; Todd I; Fairclough LC ELISA in the multiplex era: Potentials and pitfalls. Proteomics - Clinical Applications 2015, pp 406–422. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (16).Hauck TS; Giri S; Gao Y; Chan WCW Nanotechnology diagnostics for infectious diseases prevalent in developing countries. Advanced Drug Delivery Reviews 2010, pp 438–448. [DOI] [PubMed] [Google Scholar]
- (17).Bissonnette L; Bergeron MG Infectious disease management through point-of-care personalized medicine molecular diagnostic technologies. J. Pers. Med 2012, 2 (2), 50–70 DOI: 10.3390/jpm2020050. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (18).Drain PK; Hyle EP; Noubary F; Freedberg KA; Wilson D; Bishai W; Rodriguez W; Bassett IV Evaluating Diagnostic Point-of-Care Tests in Resource-Limited Settings 2015, 14 (3), 239–249 DOI: 10.1016/S1473-3099(13)70250-0.Evaluating. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (19).Schito M; Peter TF; Cavanaugh S; Piatek AS; Young GJ; Alexander H; Coggin W; Domingo GJ; Ellenberger D; Ermantraut E; Jani I V; Katamba, A.; Palamountain, K. M.; Essajee, S.; Dowdy, D. W. Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. J. Infect. Dis 2012, 205 (SUPPL. 2), 169–180 DOI: 10.1093/infdis/jis044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (20).DiMaio MA; Pereira IT; George TI; Banaei N Performance of BinaxNOW for diagnosis of malaria in a U.S. Hospital. J. Clin. Microbiol 2012, 50 (9), 2877–2880 DOI: 10.1128/JCM.01013-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (21).Delaney KP; Branson BM; Uniyal A; Phillips S; Candal D; Owen SM; Kerndt PR Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin. Infect. Dis 2011, 52 (2), 257–263 DOI: 10.1093/cid/ciq068. [DOI] [PubMed] [Google Scholar]
- (22).Wilson ML Malaria rapid diagnostic tests. Clin. Infect. Dis 2012, 54 (11), 1637–1641 DOI: 10.1093/cid/cis228. [DOI] [PubMed] [Google Scholar]
- (23).Shin DJ; Athamanolap P; Chen L; Hardick J; Lewis M; Hsieh YH; Rothman RE; Gaydos CA; Wang TH Mobile nucleic acid amplification testing (mobiNAAT) for Chlamydia trachomatis screening in hospital emergency department settings. Sci. Rep 2017, 7 (1), 1–10 DOI: 10.1038/s41598-017-04781-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (24).Abu-Salah KM; Zourob MM; Mouffouk F; Alrokayan SA; Alaamery MA; Ansari AA DNA-based nanobiosensors as an emerging platform for detection of disease. Sensors (Switzerland) 2015, 15 (6), 14539–14568 DOI: 10.3390/s150614539. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (25).Andreotti PE; Ludwig GV; Peruski AH; Tuite JJ; Morse SS; Peruski LF Immunoassay of infectious agents. Biotechniques 2003, 35 (4), 850–859. [DOI] [PubMed] [Google Scholar]
- (26).D’Orazio P Biosensors in clinical chemistry. Clin. Chim. Acta 2003, 334 (1–2), 41–69 DOI: 10.1016/S0009-8981(03)00241-9. [DOI] [PubMed] [Google Scholar]
- (27).Banala S; Arts R; Aper SJA; Merkx M No washing, less waiting: engineering biomolecular reporters for single-step antibody detection in solution. Org. Biomol. Chem 2013, 11 (44), 7642 DOI: 10.1039/c3ob41315b. [DOI] [PubMed] [Google Scholar]
- (28).Xu X; Akay A; Wei H; Wang S; Pingguan-Murphy B; Erlandsson BE; Li X; Lee W; Hu J; Wang L; Xu F Advances in Smartphone-Based Point-of-Care Diagnostics. Proc. IEEE 2015, 103 (2), 236–247 DOI: 10.1109/JPROC.2014.2378776. [DOI] [Google Scholar]
- (29).Nasir MS; Jolley ME Fluorescence polarization: an analytical tool for immunoassay and drug discovery. Comb. Chem. High Throughput Screen 1999, 2 (4), 177–190. [PubMed] [Google Scholar]
- (30).Park KS; Charles RC; Ryan ET; Weissleder R; Lee H Fluorescence polarization-based nucleic acid testing for rapid and cost-effective diagnosis of infectious disease. Chemistry (Easton) 2015, 21 (46), 16359–16363. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (31).Wei AP; Herron JN Use of Synthetic Peptides as Tracer Antigens in Fluorescence Polarization Immunoassays of High Molecular Weight Analytes. Anal. Chem 1993, 65 (23), 3372–3377 DOI: 10.1021/ac00071a007. [DOI] [PubMed] [Google Scholar]
- (32).Wang Z-H; Zhang S-X; Shen J-Z; Eremin SA Development of fluorescence polarization immunoassay for determination of pesticides and veterinary drugs. Guang Pu Xue Yu Guang Pu Fen Xi/Spectroscopy Spectr. Anal 2007, 27 (11). [PubMed] [Google Scholar]
- (33).Zhang J; Tian J; He Y; Chen S; Jiang Y; Zhao Y; Zhao S Protein-binding aptamer assisted signal amplification for the detection of influenza A (H1N1) DNA sequences based on quantum dot fluorescence polarization analysis. Analyst 2013, 138 (17), 4722 DOI: 10.1039/c3an00830d. [DOI] [PubMed] [Google Scholar]
- (34).Walker GT; Nadeau JG; Linn CP; Devlin RF; Dandliker WB Strand displacement amplification (SDA) and transient-state fluorescence polarization detection of Mycobacterium tuberculosis DNA. Clin. Chem 1996, 42 (1), 9–13. [PubMed] [Google Scholar]
- (35).Qin D; He X; Wang K; Zhao XJ; Tan W; Chen J Fluorescent nanoparticle-based indirect immunofluorescence microscopy for detection of Mycobacterium tuberculosis. J. Biomed. Biotechnol 2007, 2007 (7), 89364 DOI: 10.1155/2007/89364. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (36).Walker GT; Linn CP Detection of Mycobacterium tuberculosis DNA with thermophilic strand displacement amplification and fluorescence polarization. Clin. Chem 1996, 42 (10), 1604–1608. [PubMed] [Google Scholar]
- (37).Lucero NE; Escobar GI; Ayala SM; Paulo PS; Nielsen KH Fluorescence polarization assay for diagnosis of human brucellosis. J. Med. Microbiol 2003, 52 (10), 883–887. [DOI] [PubMed] [Google Scholar]
- (38).Chi X; Huang D; Zhao Z; Zhou Z; Yin Z; Gao J Nanoprobes for in vitro diagnostics of cancer and infectious diseases. Biomaterials 2012, 33 (1), 189–206 DOI: 10.1016/j.biomaterials.2011.09.032. [DOI] [PubMed] [Google Scholar]
- (39).Qasim Muhammad; Lim D-J; Park H; Na D Nanotechnology for Diagnosis and Treatment of Infectious Diseases. J. Nanosci. Nanotechnol 2014, 14, 7374–7387 DOI: 10.1166/jnn.2014.9578. [DOI] [PubMed] [Google Scholar]
- (40).Myers FB; Lee LP Innovations in optical microfluidic technologies for point-of-care diagnostics. Lab Chip 2008, 8 (12), 2015 DOI: 10.1039/b812343h. [DOI] [PubMed] [Google Scholar]
- (41).Takemura K; Adegoke O; Takahashi N; Kato T; Li TC; Kitamoto N; Tanaka T; Suzuki T; Park EY Versatility of a localized surface plasmon resonance-based gold nanoparticle-alloyed quantum dot nanobiosensor for immunofluorescence detection of viruses. Biosens. Bioelectron 2017, 89, 998–1005 DOI: 10.1016/j.bios.2016.10.045. [DOI] [PubMed] [Google Scholar]
- (42).Ming K; Kim J; Biondi MJ; Syed A; Chen K; Lam A; Ostrowski M; Rebbapragada A; Feld JJ; Chan WCW Integrated quantum dot barcode smartphone optical device for wireless multiplexed diagnosis of infected patients. ACS Nano 2015, 9 (3), 3060–3074 DOI: 10.1021/nn5072792. [DOI] [PubMed] [Google Scholar]
- (43).Xiong LH; Cui R; Zhang ZL; Yu X; Xie Z; Shi YB; Pang DW Uniform fluorescent nanobioprobes for pathogen detection. ACS Nano 2014, 8 (5), 5116–5124 DOI: 10.1021/nn501174g. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (44).Hsieh K; Ferguson BS; Eisenstein M; Plaxco KW; Soh HT Integrated electrochemical microsystems for genetic detection of pathogens at the point of care. Acc. Chem. Res 2015, 48 (4), 911–920 DOI: 10.1021/ar500456w. [DOI] [PubMed] [Google Scholar]
- (45).Su W; Gao X; Jiang L; Qin J Microfluidic platform towards point-of-care diagnostics in infectious diseases. Journal of Chromatography A 2015, pp 13–26. [DOI] [PubMed] [Google Scholar]
- (46).Zhang RQ; Liu SL; Zhao W; Zhang WP; Yu X; Li Y; Li AJ; Pang DW; Zhang ZL A simple point-of-care microfluidic immunomagnetic fluorescence assay for pathogens. Anal. Chem 2013, 85 (5), 2645–2651 DOI: 10.1021/ac302903p. [DOI] [PubMed] [Google Scholar]
- (47).Lagelly ET; Scherer JR; Blazej RG; Toriello NM; Diep BA; Ramchandani M; Sensabaugh GF; Riley LW; Mathies RA Integrated portable genetic analysis microsystem for pathogen/infectious disease detection. Anal. Chem 2004, 76 (11), 3162–3170 DOI: 10.1021/ac035310p. [DOI] [PubMed] [Google Scholar]
- (48).Sugino H; Ozaki K; Shirasaki Y; Arakawa T; Shoji S; Funatsu T On-chip microfluidic sorting with fluorescence spectrum detection and multiway separation. Lab Chip 2009, 9 (9), 1254–1260 DOI: 10.1039/B815765K. [DOI] [PubMed] [Google Scholar]
- (49).Kalgala GV; Huskins RJ; Preiksaitis J; Pang XL; Pilarski LM; Backhouse CJ Automated screening using microfluidic chip-based PCR and product detection to assess risk of BK virus-associated nephropathy in renal transplant recipients. Electrophoresis 2006, 27 (19), 3753–3763 DOI: 10.1002/elps.200600061. [DOI] [PubMed] [Google Scholar]
- (50).Iswardy E; Tsai TC; Cheng IF; Ho TC; Chuen Perng G; Chang HC A bead-based immunofluorescence-assay on a microfluidic dielectrophoresis platform for rapid dengue virus detection. Biosens. Bioelectron 2017, 97 (June), 400 DOI: 10.1016/j.bios.2017.05.038. [DOI] [PubMed] [Google Scholar]
- (51).Huang FC; Liao CS; Lee G Bin. An integrated microfluidic chip for DNA/RNA amplification, electrophoresis separation and on-line optical detection. Electrophoresis 2006, 27 (16), 3297–3305 DOI: 10.1002/elps.200600458. [DOI] [PubMed] [Google Scholar]
- (52).Huang S; Li C; Lin B; Qin J Microvalve and micropump controlled shuttle flow microfluidic device for rapid DNA hybridization. Lab Chip 2010, 10 (21), 2925 DOI: 10.1039/c005227b. [DOI] [PubMed] [Google Scholar]
- (53).Easley CJ; Karlinsey JM; Landers JP On-chip pressure injection for integration of infrared-mediated DNA amplification with electrophoretic separation. Lab Chip 2006, 6 (5), 601–610 DOI: 10.1039/b600039h. [DOI] [PubMed] [Google Scholar]
- (54).Soler M; Belushkin A; Cavallini A; Kebbi-Beghdadi C; Greub G; Altug H Multiplexed nanoplasmonic biosensor for one-step simultaneous detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine. Biosens. Bioelectron 2017, 94 (January), 560–567 DOI: 10.1016/j.bios.2017.03.047. [DOI] [PubMed] [Google Scholar]
- (55).Banerjee T; Sulthana S; Shelby T; Heckert B; Jewell J; Woody K; Karimnia V; McAfee J; Santra S Multiparametric Magneto-fluorescent Nanosensors for the Ultrasensitive Detection of Escherichia coli O157:H7. ACS Infect. Dis 2016, 2 (10), 667–673 DOI: 10.1021/acsinfecdis.6b00108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (56).Gharatape A; Salehi R Recent progress in theranostic applications of hybrid gold nanoparticles. European Journal of Medicinal Chemistry 2017, pp 221–233. [DOI] [PubMed] [Google Scholar]
- (57).Kim J; Jang M; Lee KG; Lee KS; Lee SJ; Ro KW; Kang IS; Jeong B. Do; Park TJ; Kim HJ; Lee J Plastic-Chip-Based Magnetophoretic Immunoassay for Point-of-Care Diagnosis of Tuberculosis. ACS Appl. Mater. Interfaces 2016, 8 (36), 23489–23497 DOI: 10.1021/acsami.6b06924. [DOI] [PubMed] [Google Scholar]
- (58).Park TJ; Lee SJ; Kim DK; Heo NS; Park JY; Lee SY Development of label-free optical diagnosis for sensitive detection of influenza virus with genetically engineered fusion protein. Talanta 2012, 89, 246–252 DOI: 10.1016/j.talanta.2011.12.021. [DOI] [PubMed] [Google Scholar]
- (59).Yu M; Wang H; Fu F; Li L; Li J; Li G; Song Y; Swihart MT; Song E Dual-Recognition Förster Resonance Energy Transfer Based Platform for One-Step Sensitive Detection of Pathogenic Bacteria Using Fluorescent Vancomycin-Gold Nanoclusters and Aptamer-Gold Nanoparticles. Anal. Chem 2017, 89 (7), 4085–4090 DOI: 10.1021/acs.analchem.6b04958. [DOI] [PubMed] [Google Scholar]
- (60).Iswardy E; Tsai TC; Cheng IF; Ho TC; Perng GC; Chang HC A bead-based immunofluorescence-assay on a microfluidic dielectrophoresis platform for rapid dengue virus detection. Biosens. Bioelectron 2017, 95 (1), 174–180 DOI: 10.1016/j.bios.2017.04.011. [DOI] [PubMed] [Google Scholar]
- (61).Park TJ; Lee SJ; Kim DK; Heo NS; Park JY; Lee SY Development of label-free optical diagnosis for sensitive detection of influenza virus with genetically engineered fusion protein. Talanta 2012, 89, 246–252 DOI: 10.1016/j.talanta.2011.12.021. [DOI] [PubMed] [Google Scholar]
- (62).Ahmed A; Rushworth JV; Hirst NA; Millner PA Biosensors for whole-cell bacterial detection. Clin. Microbiol. Rev 2014, 27 (3), 631–646 DOI: 10.1128/CMR.00120-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (63).Adkins J; Boehle K; Henry C Electrochemical paper-based microfluidic devices. Electrophoresis 2015, pp 1811–1824. [DOI] [PubMed] [Google Scholar]
- (64).Ng BYC; Xiao W; West NP; Wee EJH; Wang Y; Trau M Rapid, Single-Cell Electrochemical Detection of Mycobacterium tuberculosis Using Colloidal Gold Nanoparticles. Anal. Chem 2015, 87 (20), 10613–10618 DOI: 10.1021/acs.analchem.5b03121. [DOI] [PubMed] [Google Scholar]
- (65).Sepunaru L; Plowman BJ; Sokolov SV; Young NP; Compton RG Rapid electrochemical detection of single influenza viruses tagged with silver nanoparticles. Chem. Sci 2016, 7 (6), 3892–3899 DOI: 10.1039/C6SC00412A. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (66).Hideshima S; Hinou H; Ebihara D; Sato R; Kuroiwa S; Nakanishi T; Nishimura SI; Osaka T Attomolar detection of influenza A virus hemagglutinin human H1 and avian H5 using glycan-blotted field effect transistor biosensor. Anal. Chem 2013, 85 (12), 5641–5644 DOI: 10.1021/ac401085c. [DOI] [PubMed] [Google Scholar]
- (67).Andresen D; Balkenhohl T Biosensing for the 21st Century; 2013; Vol. 53. [Google Scholar]
- (68).Patolsky F; Zheng G; Hayden O; Lakadamyali M; Zhuang X; Lieber CM Electrical detection of single viruses. Proc. Natl. Acad. Sci. U. S. A 2004, 101 (39), 14017–14022 DOI: 10.1073/pnas.0406159101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (69).Park J; Hiep H; Woubit A; Kim M Applications of Field-Effect Transistor (FET) -Type Biosensors. Appl. Sci. Converg. Technol 2014, 23 (2), 61–71. [Google Scholar]
- (70).Tarasov A; Gray DW; Tsai MY; Shields N; Montrose A; Creedon N; Lovera P; O’Riordan A; Mooney MH; Vogel EM A potentiometric biosensor for rapid on-site disease diagnostics. Biosens. Bioelectron 2016, 79, 669–678 DOI: 10.1016/j.bios.2015.12.086. [DOI] [PubMed] [Google Scholar]
- (71).Afsahi S; Lerner MB; Goldstein JM; Lee J; Tang X; Bagarozzi DA; Pan D; Locascio L; Walker A; Barron F; Goldsmith BR Novel graphene-based biosensor for early detection of Zika virus infection. Biosens. Bioelectron 2018, 100 (June 2017), 85–88 DOI: 10.1016/j.bios.2017.08.051. [DOI] [PubMed] [Google Scholar]
- (72).Sassa F; Morimoto K; Satoh W; Suzuki H Electrochemical techniques for microfluidic applications. Electrophoresis 2008, 29 (9), 1787–1800 DOI: 10.1002/elps.200700581. [DOI] [PubMed] [Google Scholar]
- (73).Kelley SO; Mirkin CA; Walt DR; Ismagilov RF; Toner M; Sargent EH Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering. Nat. Nanotechnol 2014, 9 (12), 969–980 DOI: 10.1038/nnano.2014.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (74).Lillehoj PB; Kaplan CW; He J; Shi W; Ho C-M Rapid, Electrical Impedance Detection of Bacterial Pathogens Using Immobilized Antimicrobial Peptides. J. Lab. Autom 2013, 19 (1), 42–49 DOI: 10.1177/2211068213495207. [DOI] [PubMed] [Google Scholar]
- (75).Krejcova L; Nejdl L; Rodrigo MAM; Zurek M; Matousek M; Hynek D; Zitka O; Kopel P; Adam V; Kizek R 3D printed chip for electrochemical detection of influenza virus labeled with CdS quantum dots. Biosens. Bioelectron 2014, 54, 421–427 DOI: 10.1016/j.bios.2013.10.031. [DOI] [PubMed] [Google Scholar]
- (76).Singh R; Hong S; Jang J Label-free Detection of Influenza Viruses using a Reduced Graphene Oxide-based Electrochemical Immunosensor Integrated with a Microfluidic Platform. Sci. Rep 2017, 7 DOI: 10.1038/srep42771. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (77).Bunyakul N; Promptmas C; Baeumner AJ Microfluidic biosensor for cholera toxin detection in fecal samples. Anal. Bioanal. Chem 2015, 407 (3), 727–736 DOI: 10.1007/s00216-014-7947-9. [DOI] [PubMed] [Google Scholar]
- (78).Luo J; Fang X; Ye D; Li H; Chen H; Zhang S; Kong J A real-time microfluidic multiplex electrochemical loop-mediated isothermal amplification chip for differentiating bacteria. Biosens. Bioelectron 2014, 60, 84–91 DOI: 10.1016/j.bios.2014.03.073. [DOI] [PubMed] [Google Scholar]
- (79).Hsieh K; Patterson AS; Ferguson BS; Plaxco KW; Soh HT Rapid, sensitive, and quantitative detection of pathogenic DNA at the point of care through microfluidic electrochemical quantitative loop-mediated isothermal amplification. Angew. Chemie - Int. Ed 2012, 51 (20), 4896–4900 DOI: 10.1002/anie.201109115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (80).Cortina ME; Melli LJ; Roberti M; Mass M; Longinotti G; Tropea S; Lloret P; Serantes DAR; Salomón F; Lloret M; Caillava AJ; Restuccia S; Altcheh J; Buscaglia CA; Malatto L; Ugalde JE; Fraigi L; Moina C; Ybarra G; Ciocchini AE; Comerci DJ Electrochemical magnetic microbeads-based biosensor for point-of-care serodiagnosis of infectious diseases. Biosens. Bioelectron 2016, 80, 24–33 DOI: 10.1016/j.bios.2016.01.021. [DOI] [PubMed] [Google Scholar]
- (81).Damhorst GL; Murtagh M; Rodriguez WR; Bashir R Microfluidics and Nanotechnology for Detection of Global Infectious Diseases. Proceedings of the IEEE 2015, pp 150–160. [Google Scholar]
- (82).Bai L; Chen Y; Bai Y; Chen Y; Zhou J; Huang A Fullerene-doped polyaniline as new redox nanoprobe and catalyst in electrochemical aptasensor for ultrasensitive detection of Mycobacterium tuberculosis MPT64 antigen in human serum. Biomaterials 2017, 133, 11–19 DOI: 10.1016/j.biomaterials.2017.04.010. [DOI] [PubMed] [Google Scholar]
- (83).Fang Y-S; Chen S-Y; Huang X-J; Wang L-S; Wang H-Y; Wang J-F Simple approach for ultrasensitive electrochemical immunoassay of Clostridium difficile toxin B detection. Biosens. Bioelectron 2014, 53, 238–244 DOI: 10.1016/j.bios.2013.09.063. [DOI] [PubMed] [Google Scholar]
- (84).Cecchetto J; Fernandes FCB; Lopes R; Bueno PR The capacitive sensing of NS1 Flavivirus biomarker. Biosens. Bioelectron 2017, 87, 949–956 DOI: 10.1016/j.bios.2016.08.097. [DOI] [PubMed] [Google Scholar]
- (85).Hushegyi A; Pihíková D; Bertok T; Adam V; Kizek R; Tkac J Ultrasensitive detection of influenza viruses with a glycan-based impedimetric biosensor. Biosens. Bioelectron 2016, 79, 644–649 DOI: 10.1016/j.bios.2015.12.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (86).Shafiee H; Jahangir M; Inci F; Wang S; Willenbrecht RBM; Giguel FF; Tsibris AMN; Kuritzkes DR; Demirci U Acute on-chip HIV detection through label-free electrical sensing of viral nano-lysate. Small 2013, 9 (15), 2553–2563 DOI: 10.1002/smll.201202195. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (87).Guo X; Kulkarni A; Doepke A; Halsall HB; Iyer S; Heineman WR Carbohydrate-based label-free detection of escherichia coli ORN 178 using electrochemical impedance spectroscopy. Anal. Chem 2012, 84 (1), 241–246 DOI: 10.1021/ac202419u. [DOI] [PubMed] [Google Scholar]
- (88).Diouani MF; Ouerghi O; Refai A; Belgacem K; Tlili C; Laouini D; Essafi M Detection of ESAT-6 by a label free miniature immuno-electrochemical biosensor as a diagnostic tool for tuberculosis. Mater. Sci. Eng. C 2017, 74, 465–470 DOI: 10.1016/j.msec.2016.12.051. [DOI] [PubMed] [Google Scholar]
- (89).Torati SR; Reddy V; Yoon SS; Kim CG Electrochemical biosensor for Mycobacterium tuberculosis DNA detection based on gold nanotubes array electrode platform. Biosens. Bioelectron 2016, 78, 483–488 DOI: 10.1016/j.bios.2015.11.098. [DOI] [PubMed] [Google Scholar]
- (90).Li Y; Xiong Y; Fang L; Jiang L; Huang H; Deng J; Liang W; Zheng J An Electrochemical Strategy using Multifunctional Nanoconjugates for Efficient Simultaneous Detection of Escherichia coli O157: H7 and Vibrio cholerae O1. Theranostics 2017, 7 (4), 935–944 DOI: 10.7150/thno.17544. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (91).Laczka O; Ferraz RM; Ferrer-Miralles N; Villaverde A; Muñoz FX; Campo FJ del. Fast electrochemical detection of anti-HIV antibodies: Coupling allosteric enzymes and disk microelectrode arrays. Anal. Chim. Acta 2009, 641 (1–2), 1–6 DOI: 10.1016/j.aca.2009.03.008. [DOI] [PubMed] [Google Scholar]
- (92).Hu C; Kalsi S; Zeimpekis I; Sun K; Ashburn P; Turner C; Sutton JM; Morgan H Ultra-fast electronic detection of antimicrobial resistance genes using isothermal amplification and Thin Film Transistor sensors. Biosens. Bioelectron 2017, 96 (January), 281–287 DOI: 10.1016/j.bios.2017.05.016. [DOI] [PubMed] [Google Scholar]
- (93).Luo J; Fang X; Ye D; Li H; Chen H; Zhang S; Kong J A real-time microfluidic multiplex electrochemical loop-mediated isothermal amplification chip for differentiating bacteria. Biosens. Bioelectron 2014, 60, 84–91 DOI: 10.1016/j.bios.2014.03.073. [DOI] [PubMed] [Google Scholar]
- (94).Lee KH; Zeng H Aptamer-Based ELISA Assay for Highly Specific and Sensitive Detection of Zika NS1 Protein. Anal. Chem 2017, 89 (23), 12743–12748 DOI: 10.1021/acs.analchem.7b02862. [DOI] [PubMed] [Google Scholar]
- (95).Diouani MF; Ouerghi O; Refai A; Belgacem K; Tlili C; Laouini D; Essafi M Detection of ESAT-6 by a label free miniature immuno-electrochemical biosensor as a diagnostic tool for tuberculosis. Mater. Sci. Eng. C 2017, 74, 465–470 DOI: 10.1016/j.msec.2016.12.051. [DOI] [PubMed] [Google Scholar]
- (96).Koh I; Josephson L Magnetic Nanoparticle Sensors. Sensors 2009, 9 (10), 8130–8145 DOI: 10.3390/s91008130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (97).Perez JM; Josephson L; Weissleder R Use of magnetic nanoparticles as nanosensors to probe for molecualr interactions. ChemBioChem 2004, 5 (3), 261–264. [DOI] [PubMed] [Google Scholar]
- (98).Josephson L; Manuel Perez J; Weissleder R Magnetic nanosensors for the detection of oligonucleotide sequences. Angew. Chemie - Int. Ed 2001, 40 (17), 3204–3206 DOI: . [DOI] [PubMed] [Google Scholar]
- (99).Agiotis L; Theodorakos I; Samothrakitis S; Papazoglou S; Zergioti I; Raptis YS Magnetic manipulation of superparamagnetic nanoparticles in a microfluidic system for drug delivery applications. Journal of Magnetism and Magnetic Materials 2016, pp 956–964. [Google Scholar]
- (100).Santiesteban OJ; Kaittanis C; Perez JM Assessment of molecular interactions through magnetic relaxation. Angew. Chemie - Int. Ed 2012, 51 (27), 6728–6732 DOI: 10.1002/anie.201202077. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (101).Osterfeld SJ; Yu H; Gaster RS; Caramuta S; Xu L; Han S-J; Hall DA; Wilson RJ; Sun S; White RL; Davis RW; Pourmand N; Wang SX Multiplex protein assays based on real-time magnetic nanotag sensing. Proc. Natl. Acad. Sci 2008, 105 (52), 20637–20640 DOI: 10.1073/pnas.0810822105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (102).Lin G; Makarov D; Schmidt OG Magnetic sensing platform technologies for biomedical applications. Lab Chip 2017, 17 (11), 1884–1912 DOI: 10.1039/C7LC00026J. [DOI] [PubMed] [Google Scholar]
- (103).Krishna VD; Wu K; Perez AM; Wang JP Giant magnetoresistance-based biosensor for detection of influenza A virus. Front. Microbiol 2016, 7 (MAR), 1–8 DOI: 10.3389/fmicb.2016.00400. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (104).Rowland CE; Brown CW; Delehanty JB; Medintz IL Nanomaterial-based sensors for the detection of biological threat agents. Materials Today 2016, pp 464–477. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (105).Kearns H; Goodacre R; Jamieson L; Graham D; Faulds K SERS Detection of Multiple Anti-microbial Resistant Pathogens using Nanosensors. Anal. Chem 2017. DOI: 10.1021/acs.analchem.7b02653. [DOI] [PubMed] [Google Scholar]
- (106).Shelby T; Banerjee T; Kallu J; Sulthana S; Zegar I; Santra S Novel magnetic relaxation nanosensors: an unparalleled “spin” on influenza diagnosis. Nanoscale 2016, 8 (47), 19605–19613 DOI: 10.1039/C6NR05889B. [DOI] [PubMed] [Google Scholar]
- (107).Santiesteban OJ; Kaittanis C; Perez JM Identification of toxin inhibitors using a magnetic nanosensor-based assay. Small 2014, 10 (6), 1202–1211 DOI: 10.1002/smll.201301824. [DOI] [PubMed] [Google Scholar]
- (108).Huang C-C; Zhou X; Hall DA Giant Magnetoresistive Biosensors for Time-Domain Magnetorelaxometry: A Theoretical Investigation and Progress Toward an Immunoassay. Sci. Rep 2017, 7, 45493 DOI: 10.1038/srep45493. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (109).Barroso TG; Martins RC; Fernandes E; Cardoso S; Rivas J; Freitas PP Detection of BCG bacteria using a magnetoresistive biosensor: a step towards a fully electronic platform for tuberculosis point-of-care detection. Biosens. Bioelectron 2017. DOI: 10.1016/j.bios.2017.09.004. [DOI] [PubMed] [Google Scholar]
- (110).Tian B; Qiu Z; Ma J; Zardán Gómez de la Torre, T.; Johansson, C.; Svedlindh, P.; Strömberg, M. Attomolar Zika virus oligonucleotide detection based on loop-mediated isothermal amplification and AC susceptometry. Biosens. Bioelectron 2016, 86, 420–425 DOI: 10.1016/j.bios.2016.06.085. [DOI] [PubMed] [Google Scholar]
- (111).Bejhed RS; Zardán Gómez De La Torre T; Donolato M; Hansen MF; Svedlindh P; Strömberg M Turn-on optomagnetic bacterial DNA sequence detection using volume-amplified magnetic nanobeads. Biosens. Bioelectron 2015, 66, 405–411 DOI: 10.1016/j.bios.2014.11.048. [DOI] [PubMed] [Google Scholar]
- (112).Tian B; Bejhed RS; Svedlindh P; Stromberg M Blu-ray optomagnetic measurement based competitive immunoassay for Salmonella detection. Biosens. Bioelectron 2016, 77, 32–39 DOI: 10.1016/j.bios.2015.08.070. [DOI] [PubMed] [Google Scholar]
- (113).Lee H; Sun E; Ham D; Weissleder R Chip–NMR biosensor for detection and molecular analysis of cells. Nat. Med 2008, 14 (8), 869–874 DOI: 10.1038/nm.1711. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (114).Liong M; Hoang AN; Chung J; Gural N; Ford CB; Min C; Shah RR; Ahmad R; Fernandez-Suarez M; Fortune SM; Toner M; Lee H; Weissleder R Magnetic barcode assay for genetic detection of pathogens. Nat. Commun 2013, 4, 1752 DOI: 10.1038/ncomms2745. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (115).Aytur T; Foley J; Anwar M; Boser B; Harris E; Beatty PR A novel magnetic bead bioassay platform using a microchip-based sensor for infectious disease diagnosis. J. Immunol. Methods 2006, 314 (1–2), 21–29 DOI: 10.1016/j.jim.2006.05.006. [DOI] [PubMed] [Google Scholar]
- (116).Shelby T; Banerjee T; Kallu J; Sulthana S; Zegar I; Santra S Novel magnetic relaxation nanosensors: An unparalleled “spin” on influenza diagnosis. Nanoscale 2016, 8 (47), 19605–19613 DOI: 10.1039/c6nr05889b. [DOI] [PubMed] [Google Scholar]
- (117).Sharma S; Zapatero-Rodriguez J; Estrela P; O’Kennedy R Point-of-Care diagnostics in low resource settings: Present status and future role of microfluidics. Biosensors 2015, 5 (3), 577–601 DOI: 10.3390/bios5030577. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (118).Koczula KM; Gallotta A Lateral flow assays. Essays Biochem 2016, 60 (1), 111–120 DOI: 10.1042/EBC20150012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (119).Shah M; Hanrahan C; Wang ZY; Dendukuri N; Lawn SD; Denkinger CM; Steingart KR Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults. Cochrane Database Syst. Rev 2016, 2016 (5) DOI: 10.1002/14651858.CD011420.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (120).Hanifa Y; Fielding KL; Chihota VN; Adonis L; Charalambous S; Karstaedt A; McCarthy K; Nicol MP; Ndlovu NT; Sahid F; Churchyard GJ; Grant AD Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLoS One 2016, 11 (6), 1–12 DOI: 10.1371/journal.pone.0156866. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (121).World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV: policy 2015, 1–74 DOI: 978 92 4 150963 3. [Google Scholar]
- (122).Gonzalez JM; Francis B; Burda S; Hess K; Behera D; Gupta D; Agarwal AN; Verma I; Verma A; Myneedu VP; Niedbala S; Laal S Development of a POC Test for TB Based on Multiple Immunodominant Epitopes of M. tuberculosis Specific Cell-Wall Proteins. PLoS One 2014, 9 (9), 1–10 DOI: 10.1371/journal.pone.0106279. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (123).Le TT; Chang P; Benton D; John W; Iqbal M; Edward A; Cass G Dual Recognition Element Lateral Flow Assay (DRELFA) - Towards Multiplex Strain Specific Influenza Virus Detection. Anal. Chem 2017, 89 (12), 6781–6786 DOI: 10.1021/acs.analchem.7b01149. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (124).Yeo S; Choi K; Cuc BT; Hong NN; Bao DT; Minh N Smartphone-Based Fluorescent Diagnostic System for Highly Pathogenic H5N1 Viruses. Theranostics 2016, 6 (2) DOI: 10.7150/thno.14023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (125).Wang Y; Li H; Wang Y; Zhang L; Xu J; Ye C Loop-mediated isothermal amplification label-based gold nanoparticles lateral flow biosensor for detection of Enterococcus faecalis and Staphylococcus aureus. Front. Microbiol 2017, 8 (FEB) DOI: 10.3389/fmicb.2017.00192. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (126).Wang Y; Li H; Wang Y; Li H; Luo L; Xu J; Ye C Development of multiple cross displacement amplification label-based gold nanoparticles lateral flow biosensor for detection of Listeria monocytogenes. Int. J. Nanomedicine 2017, 12, 473–486 DOI: 10.2147/IJN.S123625. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (127).Wang Y; Wang Y; Xu J; Ye C Development of Multiple Cross Displacement Amplification Label-Based Gold Nanoparticles Lateral Flow Biosensor for Detection of Shigella spp. Front. Microbiol 2016, 7 (November), 1834 DOI: 10.3389/fmicb.2016.01834. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (128).Yen C-W; de Puig H; Tam JO; Gómez-Márquez J; Bosch I; Hamad-Schifferli K; Gehrke L Multicolored silver nanoparticles for multiplexed disease diagnostics: distinguishing dengue, yellow fever, and Ebola viruses. Lab Chip 2015, 15 (7), 1638–1641 DOI: 10.1039/C5LC00055F. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (129).Nurul Najian AB; Engku Nur Syafirah EAR; Ismail N; Mohamed M; Yean CY Development of multiplex loop mediated isothermal amplification (m-LAMP) label-based gold nanoparticles lateral flow dipstick biosensor for detection of pathogenic Leptospira. Anal. Chim. Acta 2016, 903, 142–148 DOI: 10.1016/j.aca.2015.11.015. [DOI] [PubMed] [Google Scholar]
- (130).Lin C; Zhang Y; Zhou X; Yao B; Fang Q Naked-eye detection of nucleic acids through rolling circle amplification and magnetic particle mediated aggregation. Biosens. Bioelectron 2013, 47, 515–519 DOI: 10.1016/j.bios.2013.03.056. [DOI] [PubMed] [Google Scholar]
- (131).Ding X; Wu W; Zhu Q; Zhang T; Jin W; Mu Y Mixed-Dye-Based Label-Free and Sensitive Dual Fluorescence for the Product Detection of Nucleic Acid Isothermal Multiple-Self-Matching-Initiated Amplification. Anal. Chem 2015, 87 (20), 10306–10314 DOI: 10.1021/acs.analchem.5b02112. [DOI] [PubMed] [Google Scholar]
- (132).Wang YF; Pang DW; Zhang ZL; Zheng HZ; Cao JP; Shen JT Visual gene diagnosis of HBV and HCV based on nanoparticle probe amplification and silver staining enhancement. J. Med. Virol 2003, 70 (2), 205–211 DOI: 10.1002/jmv.10379. [DOI] [PubMed] [Google Scholar]
- (133).Ng BYC; Wee EJH; West NP; Trau M Naked-Eye Colorimetric and Electrochemical Detection of Mycobacterium tuberculosis—toward Rapid Screening for Active Case Finding. ACS Sensors 2016, 1 (2), 173–178 DOI: 10.1021/acssensors.5b00171. [DOI] [Google Scholar]
- (134).Baptista PV; Koziol-Montewka M; Paluch-Oles J; Doria G; Franco R Gold-nanoparticle-probe-based assay for rapid and direct detection of Mycobacterium tuberculosis DNA in clinical samples. Clinical Chemistry 2006, pp 1433–1434. [DOI] [PubMed] [Google Scholar]
- (135).Le TT; Adamiak B; Benton DJ; Johnson CJ; Sharma S; Fenton R; McCauley JW; Iqbal M; Cass AEG Aptamer-based biosensors for the rapid visual detection of flu viruses. Chem. Commun 2014, 50 (98), 15533–15536 DOI: 10.1039/C4CC07888H. [DOI] [PubMed] [Google Scholar]
- (136).Yaren O; Alto BW; Gangodkar PV; Ranade SR; Patil KN; Bradley KM; Yang Z; Phadke N; Benner SA Point of sampling detection of Zika virus within a multiplexed kit capable of detecting dengue and chikungunya. BMC Infect. Dis 2017, 17 (1), 293 DOI: 10.1186/s12879-017-2382-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (137).Chen J; Alcaine SD; Jackson AA; Rotello VM; Nugen SR Development of Engineered Bacteriophages for Escherichia coli Detection and High-Throughput Antibiotic Resistance Determination. ACS Sensors 2017, 2 (4), 484–489 DOI: 10.1021/acssensors.7b00021. [DOI] [PubMed] [Google Scholar]
- (138).Driskell JD; Jones CA; Tompkins SM; Tripp RA One-step assay for detecting influenza virus using dynamic light scattering and gold nanoparticles. Analyst 2011, 136 (15), 3083 DOI: 10.1039/c1an15303j. [DOI] [PubMed] [Google Scholar]
- (139).Bosch I; De Puig H; Hiley M; Carré-Camps M; Perdomo-Celis F; Narváez CF; Salgado DM; Senthoor D; O’Grady M; Phillips E; Durbin A; Fandos D; Miyazaki H; Yen CW; Gélvez-Ramírez M; Warke RV; Ribeiro LS; Teixeira MM; Almeida RP; Muñóz-Medina JE; Ludert JE; Nogueira ML; Colombo TE; Terzian ACB; Bozza PT; Calheiros AS; Vieira YR; Barbosa-Lima G; Vizzoni A; Cerbino-Neto J; Bozza FA; Souza TML; Trugilho MRO; Filippis AMB; Sequeira PC; Marques ETA; Magalhaes T; Díaz FJ; Restrep BN; Marín K; Mattar S; Olson D; Asturias EJ; Lucera M; Singla M; Medigeshi GR; Bosch N; Tam J; Gómez-Márquez J; Clavet C; Villar L; Hamad-Schifferli K; Gehrke L Rapid antigen tests for dengue virus serotypes and Zika virus in patient serum. Sci. Transl. Med 2017, No. September DOI: 10.1126/scitranslmed.aan1589. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (140).Duncan B; Le NDB; Alexander C; Gupta A; Yesilbag Tonga G; Yazdani M; Landis RF; Wang LS; Yan B; Burmaoglu S; Li X; Rotello VM Sensing by Smell: Nanoparticle-Enzyme Sensors for Rapid and Sensitive Detection of Bacteria with Olfactory Output. ACS Nano 2017, 11 (6), 5339–5343 DOI: 10.1021/acsnano.7b00822. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (141).Barbé B; Verdonck K; El-Safi S; Khanal B; Teav S; Lilo Kalo JR; Ravinetto R; Chappuis F; Boelaert M; Jacobs J Rapid Diagnostic Tests for Neglected Infectious Diseases: Case Study Highlights Need for Customer Awareness and Postmarket Surveillance. PLoS Negl. Trop. Dis 2016, 10 (11), 1–8 DOI: 10.1371/journal.pntd.0004655. [DOI] [PMC free article] [PubMed] [Google Scholar]